Identification of an HLA-A*11:01-restricted neoepitope of mutant PIK3CA and its specific T cell receptors for cancer immunotherapy targeting hotspot driver mutations
(1) Shen M (2) Chen S (3) Han X (4) Hao Y (5) Wang J (6) Li L (7) Chen T (8) Wang B (9) Zou L (10) Zhang T (11) Zhang W (12) Han X (13) Wang W (14) Yu H (15) Li K (16) Liu S (17) Jin A
(1) Shen M (2) Chen S (3) Han X (4) Hao Y (5) Wang J (6) Li L (7) Chen T (8) Wang B (9) Zou L (10) Zhang T (11) Zhang W (12) Han X (13) Wang W (14) Yu H (15) Li K (16) Liu S (17) Jin A
Hotspot driver mutations presented by human leukocyte antigens might be recognized by anti-tumor T cells. Based on their advantages of tumor-specificity and immunogenicity, neoantigens derived from hotspot mutations, such as PIK3CA(H1047L), may serve as emerging targets for cancer immunotherapies. NetMHCpan V4.1 was utilized for predicting neoepitopes of PIK3CA hotspot mutation. Using in vitro stimulation, antigen-specific T cells targeting the HLA-A*11:01-restricted PIK3CA mutation were isolated from healthy donor-derived peripheral blood mononuclear cells. T cell receptors (TCRs) were cloned using single-cell PCR and sequencing. Their functionality was assessed through T cell activation markers, cytokine production and cytotoxic response to cancer cell lines pulsed with peptides or transduced genes of mutant PIK3CA. Immunogenic mutant antigens from PIK3CA and their corresponding CD8(+) T cells were identified. These PIK3CA mutation-specific CD8(+) T cells were subsequently enriched, and their TCRs were isolated. The TCR clones exhibited mutation-specific and HLA-restricted reactivity, demonstrating varying degrees of functional avidity. Identified TCR genes were transferred into CD8(+) Jurkat cells and primary T cells deficient of endogenous TCRs. TCR-expressing cells demonstrated specific recognition and reactivity against the PIK3CA(H1047L) peptide presented by HLA-A*11:01-expressing K562 cells. Furthermore, mutation-specific TCR-T cells demonstrated an elevation in cytokine production and profound cytotoxic effects against HLA-A*11:01(+) malignant cell lines harboring PIK3CA(H1047L). Our data demonstrate the immunogenicity of an HLA-A*11:01-restricted PIK3CA hotspot mutation and its targeting therapeutic potential, together with promising candidates of TCR-T cell therapy.
Author Info:
(1) Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. (2) Department of Immunology, College of Basic Medici
ne, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (3) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (4) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (5) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (6) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (7) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (8) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (9) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (10) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (11) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (12) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (13) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. (14) Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. (15) Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. (16) Department of Breast and Thyroid Surgery, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China. liushengchun1968@163.com. (17) Department of Immunology, College of Basic Medicine, Chongqing Medical University, Chongqing, China. aishunjin@cqmu.edu.cn. Chongqing Key Laboratory of Basic and Translational Research of Tumor Immunology, Chongqing Medical University, Chongqing, China. aishunjin@cqmu.edu.cn.
Citation: Cancer Immunol Immunother 2024 Jun 4 73:150 Epub06/04/2024
